Geneos Wealth Management Inc. Cara Therapeutics, Inc. Transaction History

Geneos Wealth Management Inc.

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$9.94 - $12.65 $2,683 - $3,415	-270 Reduced 13.11%	1,790 $21,000
Q4 2021 Feb 09, 2022	SELL	$11.99 - $18.14 $12,409 - $18,774	-1,035 Reduced 33.44%	2,060 $25,000
Q3 2021 Nov 09, 2021	SELL	$11.55 - $16.06 $4,620 - $6,423	-400 Reduced 11.44%	3,095 $47,000
Q2 2021 Jul 08, 2021	SELL	$12.38 - $29.19 $12,961 - $30,561	-1,047 Reduced 23.05%	3,495 $50,000
Q1 2021 Jun 17, 2021	SELL	$15.07 - $21.71 $8,318 - $11,983	-552 Reduced 10.84%	4,542 $58,000
Q4 2020 May 19, 2021	BUY	$12.72 - $16.16 $13,317 - $16,919	1,047 Added 25.87%	5,094 $81,000
Q2 2020 Sep 07, 2021	SELL	$12.39 - $17.33 $2,787 - $3,899	-225 Reduced 5.27%	4,047 $68,000
Q4 2019 Sep 07, 2021	BUY	$16.11 - $25.98 $805 - $1,299	50 Added 1.18%	4,272 $70,000
Q3 2019 Sep 07, 2021	SELL	$18.28 - $26.91 $5,027 - $7,400	-275 Reduced 6.12%	4,222 $78,000
Q4 2018 Sep 07, 2021	SELL	$12.45 - $23.47 $16,795 - $31,661	-1,349 Reduced 23.08%	4,497 $57,000
Q3 2018 Sep 07, 2021	BUY	$17.57 - $23.95 $16,252 - $22,153	925 Added 18.8%	5,846 $140,000
Q1 2018 Sep 07, 2021	SELL	$11.77 - $16.08 $33,556 - $45,844	-2,851 Reduced 36.68%	4,921 $60,000
Q4 2017 Sep 07, 2021	BUY	$11.86 - $14.08 $21,941 - $26,048	1,850 Added 31.24%	7,772 $95,000
Q3 2017 Sep 07, 2021	SELL	$12.6 - $16.34 $239 - $310	-19 Reduced 0.32%	5,922 $81,000
Q2 2017 Sep 07, 2021	BUY	N/A	1,262 Added 26.97%	5,941 $91,000
Q1 2017 Sep 07, 2021	BUY	N/A	1,989 Added 73.94%	4,679 $86,000
Q4 2016 Sep 07, 2021	BUY	N/A	1,575 Added 141.26%	2,690 $24,000
Q3 2016 Sep 07, 2021	BUY	N/A	1,115	1,115 $9,000

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

Stay updated on Geneos Wealth Management Inc. with notifications on news.